Literature DB >> 24613044

Pulmonary arterial hypertension and systemic sclerosis relation: a single centre experience.

Nalan Demir1, Ali Şahin2, Orhan Küçükşahin2, Oya Kayacan1, İrem Dinçer3, Tamer Sayın3, Demet Karnak4, Murat Turgay2.   

Abstract

AIM: In systemic sclerosis (SSc), this single-centre study aimed to define the frequency and association of pulmonary arterial hypertension (PAH), occurring either alone in SSc-PAH or together with interstitial lung disease (ILD-PH). MATERIAL-
METHODS: SSc cases between the years 1990-2011 were reviewed, retrospectively. Patients' clinical, laboratory findings, Modified Rodnan Skin Score and Medsger score, 6-minute walk distance (6MWD), carbon monoxide diffusion test (DLCO), echocardiography, thorax HRCT, and right heart catheterisation findings were recorded.
RESULTS: One hundred and forty-one cases (F/M:124/17, diffuse cutaneous SSc (DcSSc)/limited cutaneous SSc (LcSSc): 84/57) were included in the study with the mean age of 52.70±15.17 years and disease duration of 107.07±99.44 months. PaO₂, FEV1 and FVC were lower in DcSSc (p<0.05) as compared to LcSSc, but DLCO and 6MWD did not differ significantly, between the two forms. Ground glass opacity (64.7%) and interlobular septal thickening (58.8%) were the most frequent findings on HRCT of such subjects. PAH was detected in 34 subjects (24.1%). Seven of them had SSc associated PAH (SSc-PAH) and 27 ILD-PH. Both frequencies were similar between DcSSc and LcSSc. Mean sPAP was higher in SSc-PAH.
CONCLUSION: PAH was observed in approximately one fourth of patients; therefore advanced cardio-pulmonary investigation should be routinely performed in the SSc patients' management.
Copyright © 2014 Australian and New Zealand Society of Cardiac and Thoracic Surgeons (ANZSCTS) and the Cardiac Society of Australia and New Zealand (CSANZ). Published by Elsevier B.V. All rights reserved.

Entities:  

Keywords:  Diffuse cutaneous scleroderma; Interstitial lung disease; Limited cutaneous scleroderma; Pulmonary arterial hypertension; Systemic sclerosis

Mesh:

Year:  2014        PMID: 24613044     DOI: 10.1016/j.hlc.2014.02.002

Source DB:  PubMed          Journal:  Heart Lung Circ        ISSN: 1443-9506            Impact factor:   2.975


  5 in total

1.  Interstitial lung disease in systemic sclerosis: data from the spanish scleroderma study group.

Authors:  D Sánchez-Cano; N Ortego-Centeno; J L Callejas; V Fonollosa Plá; R Ríos-Fernández; C Tolosa-Vilella; G Espinosa-Garriga; D Colunga-Argüelles; M V Egurbide-Arberas; M Rubio-Rivas; M Freire; J J Ríos-Blanco; L Trapiella-Martínez; M Rodríguez-Carballeira; A Marín-Ballvé; X Pla-Salas; C P Simeón-Aznar
Journal:  Rheumatol Int       Date:  2018-01-10       Impact factor: 2.631

2.  Perceptions of received information, social support, and coping in patients with pulmonary arterial hypertension or chronic thromboembolic pulmonary hypertension.

Authors:  Bodil Ivarsson; Björn Ekmehag; Roger Hesselstrand; Göran Rådegran; Trygve Sjöberg
Journal:  Clin Med Insights Circ Respir Pulm Med       Date:  2014-10-23

3.  MRI assessment of aortic flow in patients with pulmonary arterial hypertension in response to exercise.

Authors:  Jacob A Macdonald; Christopher J Franҫois; Omid Forouzan; Naomi C Chesler; Oliver Wieben
Journal:  BMC Med Imaging       Date:  2018-12-22       Impact factor: 1.930

4.  Neutrophilic Alveolitis and High Serum Pro-Brain Natriuretic Peptide Level may be Indicators of Pulmonary Functional Impairment in Connective Tissue Disorders.

Authors:  Serap Unculu; Özlem Erçen Diken; Aydın Çiledağ; Aydan Ikincioğullari; Demet Karnak; Oya Kayacan; Murat Turgay
Journal:  Arch Rheumatol       Date:  2015-08-31       Impact factor: 1.472

Review 5.  Novel Therapeutic Strategies for Reducing Right Heart Failure Associated Mortality in Fibrotic Lung Diseases.

Authors:  Ayodeji Adegunsoye; Matthew Levy; Olusegun Oyenuga
Journal:  Biomed Res Int       Date:  2015-10-25       Impact factor: 3.411

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.